

CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2013/114403 A8**

(43) International Publication Date  
8 August 2013 (08.08.2013)

- (51) International Patent Classification:  
*C07D 231/54* (2006.01) *A61K 31/416* (2006.01)  
*C07D 409/04* (2006.01) *A61P 3/10* (2006.01)
- (21) International Application Number: PCT/IN2013/000056
- (22) International Filing Date: 29 January 2013 (29.01.2013)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
0262/DEL/2012 31 January 2012 (31.01.2012) IN
- (71) Applicant: **COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH** [IN/IN]; Anusandhan Bhawan, Rafi Marg, New Delhi 110001 (IN).
- (72) Inventors: **GOEL, Atul**; Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173, Lucknow 226001 (IN). **TANEJA, Gaurav**; Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173, Lucknow 226001 (IN). **RAHUJA, Neha**; Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173, Lucknow 226001 (IN). **RAWAT, Arun, Kumar**; Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173, Lucknow 226001 (IN). **JAISWAL, Natasha**; Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173, Lucknow 226001 (IN). **TAMRAKAR, Akhilesh, Kumar**; Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173, Lucknow 226001 (IN). **SRIVASTAVA, Arvind, Kumar**; Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173, Lucknow 226001 (IN).
- (74) Agent: **DHAWAN, Ramesh, C.**; Lall Lahiri & Salhotra, Plot No. B-28, Sector - 32, Institutional Area, Gurgaon 122001 (IN).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
  - *of inventorship (Rule 4.17(iv))*
- Published:**
- *with international search report (Art. 21(3))*
- (48) Date of publication of this corrected version: 3 October 2013
- (15) Information about Correction: see Notice of 3 October 2013

(54) Title: SUBSTITUTED 4,5-DIHYDRO-2H-BENZO[E]INDAZOLE-9-CARBOXYLATES FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS

(57) Abstract: The present invention relates to the development of novel substituted 4,5-dihydro-2H-benzo[e]indazole-9-carboxylates, which can be used as therapeutic agents for the treatment and prevention of metabolic disorders, and a process of preparing said novel compounds. More particularly, the present invention relates to substituted 4,5-dihydro-2H-benzo[e]indazole-9-carboxylates and their related compounds, processes for preparing the said compounds and to their use in the treatment of diabetes and related metabolic disorders.



WO 2013/114403 A8